Prurigo nodularis: an update on etiopathogenesis and therapy

References

• Weisshaar E, Szepietowski JC, Darsow U, Misery L, Wallengren J, Mettang T, et al. European guideline on chronic pruritus. Acta Derm Venereol. 2012;92:563–581.
   PubMed Web of Science ®Google Scholar
• Iking A, Grundmann S, Chatzigeorgakidis E, Phan NQ, Klein D, Ständer S. Prurigo as a symptom of atopic and non-atopic diseases: aetiological survey in a consecutive cohort of 108 patients. J Eur Acad Dermatol Venereol. 2013;27:550–557.
   PubMed Web of Science ®Google Scholar
• Ständer S, Stumpf A, Osada N, Wilp S, Chatzigeorgakidis E, Pfleiderer B. Gender differences in chronic pruritus: Women present different morbidity, more scratch lesions and higher burden. Br J Dermatol. 2013;168:1273–1280.
   PubMed Web of Science ®Google Scholar
• Weigelt N, Metze D, Ständer S. Prurigo nodularis: systematic analysis of 58 histological criteria in 136 patients. J Cutan Pathol. 2010;37:578–586.
   PubMed Web of Science ®Google Scholar
• Winhoven SM, Gawkrodger DJ. Nodular prurigo: metabolic diseases are a common association. Clin Exp Dermatol. 2007;32:224–225.
   Google Scholar
• Pugliarello S, Cozzi A, Gisondi P, Girolomoni G. Phenotypes of atopic dermatitis. J Dtsch Dermatol Ges. 2011;9:12–20.
   PubMed Web of Science ®Google Scholar
• Yosipovitch G, Samuel LS. Neuropathic and psychogenic itch. Dermatol Ther. 2008;21:32–41.
   PubMed Web of Science ®Google Scholar
• Bharati A, Wilson NJE. Peripheral neuropathy associated with nodular prurigo. Clin Exp Dermatol. 2007;32:67–70.
   Google Scholar
• Liang Y, Jacobi HH, Reimert CM, Haak-Frendscho M, Marcusson JA, Johansson O. CGRP-immunoreactive nerves in prurigo nodularis--an exploration of neurogenic inflammation. J Cutan Pathol. 2000;27:359–366.
   PubMed Web of Science ®Google Scholar
• Johansson O, Liang Y, Marcusson JA, Reimert CM. Eosinophil cationic protein- and eosinophil-derived neurotoxin/eosinophil protein X-immunoreactive eosinophils in prurigo nodularis. Arch Dermatol Res. 2000;292:371–378.
   PubMed Web of Science ®Google Scholar
• Haas S, Capellino S, Phan NQ, Böhm M, Luger TA, Straub RH, et al. Low density of sympathetic nerve fibers relative to substance P-positive nerve fibers in lesional skin of chronic pruritus and prurigo nodularis. J Dermatol Sci. 2010;58:193–197.
   PubMed Web of Science ®Google Scholar
• Emtestam L, Hagströmer L, Dou Y-C, Sartorius K, Johansson O. PGP 9.5 distribution patterns in biopsies from early lesions of atopic dermatitis. Arch Dermatol Res. 2012;304:781–785.
   Google Scholar
• Johansson O, Liang Y, Emtestam L. Increased nerve growth factor- and tyrosine kinase A-like immunoreactivities in prurigo nodularis skin -- an exploration of the cause of neurohyperplasia. Arch Dermatol Res. 2002;293:614–619.
   PubMed Web of Science ®Google Scholar
• Schuhknecht B, Marziniak M, Wissel A, Phan NQ, Pappai D, Dangelmaier J, et al. Reduced intraepidermal nerve fibre density in lesional and nonlesional prurigo nodularis skin as a potential sign of subclinical cutaneous neuropathy. Br J Dermatol. 2011;165:85–91.
   PubMed Web of Science ®Google Scholar
• Ikoma A, Steinhoff M, Ständer S, Yosipovitch G, Schmelz M. The neurobiology of itch. Nat Rev Neurosci. 2006;7:535–547.
   PubMed Web of Science ®Google Scholar
• Abadía Molina F, Burrows NP, Jones RR, Terenghi G, Polak JM. Increased sensory neuropeptides in nodular prurigo: a quantitative immunohistochemical analysis. Br J Dermatol. 1992;127:344–351.
   PubMed Web of Science ®Google Scholar
• Takada S, Kou K, Ikezawa Z, Aihara M. Aberrant epidermal expression of semaphorin 3A and nerve growth factor in prurigo nodularis. J Dermatol. 2013;40:1–2.
   Google Scholar
• Gencoglan G, Inanir I, Gunduz K. Therapeutic hotline: Treatment of prurigo nodularis and lichen simplex chronicus with gabapentin. Dermatol Ther. 2010;23:194–198.
   PubMed Web of Science ®Google Scholar
• Mazza M, Guerriero G, Marano G, Janiri L, Bria P, Mazza S. Treatment of prurigo nodularis with pregabalin. J Clin Pharm Ther. 2013;38:16–18.
   PubMed Web of Science ®Google Scholar
• Ständer S, Luger T, Metze D. Treatment of prurigo nodularis with topical capsaicin. J Am Acad Dermatol. 2001;44:471–478.
   PubMed Web of Science ®Google Scholar
• Hoeijmakers JG, Faber CG, Lauria G, Merkies IS, Waxman SG. Small-fibre neuropathies--advances in diagnosis, pathophysiology and management. Nat Rev Neurol. 2012;8:369–379.
   Google Scholar
• Fukushi S, Yamasaki K, Aiba S. Nuclear localization of activated STAT6 and STAT3 in epidermis of prurigo nodularis. Br J Dermatol. 2011;165:990–996.
   PubMed Web of Science ®Google Scholar
• Sestito R, Madonna S, Scarponi C, Cianfarani F, Failla CM, Cavani A, et al. STAT3-dependent effects of IL-22 in human keratinocytes are counterregulated by sirtuin 1 through a direct inhibition of STAT3 acetylation. FASEB J. 2011;25:916–927.
   PubMed Web of Science ®Google Scholar
• Sonkoly E, Muller A, Lauerma AI, Pivarcsi A, Soto H, Kemeny L, et al. IL-31: a new link between T cells and pruritus in atopic skin inflammation. J Allergy Clin Immunol. 2006;117:411–417.
   PubMed Web of Science ®Google Scholar
• Saraceno R, Chiricozzi A, Nisticò SP, Tiberti S, Chimenti S. An occlusive dressing containing betamethasone valerate 0.1% for the treatment of prurigo nodularis. J Dermatolog Treat. 2010;21:363–366.
   PubMed Web of Science ®Google Scholar
• Wong SS, Goh CL. Double-blind, right/left comparison of calcipotriol ointment and betamethasone ointment in the treatment of Prurigo nodularis. Arch Dermatol. 2000;136:807–808.
   Google Scholar
• Ständer S, Schürmeyer-Horst F, Luger TA, Weisshaar E. Treatment of pruritic diseases with topical calcineurin inhibitors. Ther Clin Risk Manag. 2006;2:213–218.
   PubMedGoogle Scholar
• Razeghi E, Eskandari D, Ganji MR, Meysamie AP, Togha M, Khashayar P. Gabapentin and uremic pruritus in hemodialysis patients. Ren Fail. 2009;31:85–90.
   PubMed Web of Science ®Google Scholar
• Ahuja RB, Gupta GK. A four arm, double blind, randomized and placebo controlled study of pregabalin in the management of post-burn pruritus. Burns. 2013;39:24–29.
   Google Scholar
• Chen M, Doherty SD, Hsu S. Innovative uses of thalidomide. Dermatol Clin. 2010;28:577–586.
   PubMedGoogle Scholar
• Andersen TP, Fogh K. Thalidomide in 42 patients with prurigo nodularis Hyde. Dermatology. 2011;223:107–112.
   PubMed Web of Science ®Google Scholar
• Taefehnorooz H, Truchetet F, Barbaud A, Schmutz J-L, Bursztejn A-C. Efficacy of thalidomide in the treatment of prurigo nodularis. Acta Derm Venereol. 2011;91:344–345.
   PubMed Web of Science ®Google Scholar
• Doherty SD, Hsu S. A case series of 48 patients treated with thalidomide. J Drugs Dermatol. 2008;7:769–773.
   PubMed Web of Science ®Google Scholar
• Lan C-CE, Lin C-L, Wu C-S, Chai C-Y, Chen W-T, Chen G-S. Treatment of idiopathic prurigo nodularis in Taiwanese patients with low-dose thalidomide. J Dermatol. 2007;34:237–242.
   Google Scholar
• Sharma NL, Sharma VC, Mahajan VK, Shanker V, Ranjan N, Gupta M. Thalidomide: an experience in therapeutic outcome and adverse reactions. J Dermatolog Treat. 2007;18:335–340.
   PubMed Web of Science ®Google Scholar
• Maurer T, Poncelet A, Berger T. Thalidomide treatment for prurigo nodularis in human immunodeficiency virus-infected subjects: efficacy and risk of neuropathy. Arch Dermatol. 2004;140:845–849.
   PubMedGoogle Scholar
• Ständer S, Siepmann D, Herrgott I, Sunderkötter C, Luger TA. Targeting the neurokinin receptor 1 with aprepitant: a novel antipruritic strategy. PLoS One. 2010;5:e10968.
   PubMed Web of Science ®Google Scholar
• Phan NQ, Bernhard JD, Luger TA, Ständer S. Antipruritic treatment with systemic μ-opioid receptor antagonists: a review. J Am Acad Dermatol. 2010;63:680–688.
   PubMed Web of Science ®Google Scholar
• Brune A, Metze D, Luger TA, Ständer S. Antipruritic therapy with the oral opioid receptor antagonist naltrexone. Open, non-placebo controlled administration in 133 patients. Hautarzt. 2004;55:1130–1136.
   Google Scholar
• Hammes S, Hermann J, Roos S, Ockenfels HM. UVB 308-nm excimer light and bath PUVA: combination therapy is very effective in the treatment of prurigo nodularis. J Eur Acad Dermatol Venereol. 2011;25:799–803.
   PubMed Web of Science ®Google Scholar
• Bruni E, Caccialanza M, Piccinno R. Phototherapy of generalized prurigo nodularis. Clin Exp Dermatol. 2010;35:549–550.
   Google Scholar
• Cassano N, Tessari G, Vena GA, Girolomoni G. Chronic pruritus in the absence of specific skin disease: an update on pathophysiology, diagnosis, and therapy. Am J Clin Dermatol. 2010;11:399–411.
   PubMed Web of Science ®Google Scholar
• Siepmann D, Luger TA, Ständer S. Antipruritic effect of cyclosporine microemulsion in prurigo nodularis: results of a case series. J Dtsch Dermatol Ges. 2008;6:941–946.
   PubMedGoogle Scholar
• Horiuchi Y, Bae S, Katayama I. Uncontrollable prurigo nodularis effectively treated by roxithromycin and tranilast. J Drugs Dermatol. 2006;5:363–365.
   Google Scholar
• Dawn AG, Yosipovitch G. Butorphanol for treatment of intractable pruritus. J Am Acad Dermatol. 2006;54:527–531.
   PubMed Web of Science ®Google Scholar